^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | BL-M07D1 (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Excerpt:
...Patients with histologically and/or cytologically confirmed, unresectable, locally advanced or metastatic HER2-positive/low-expressing urinary and gastrointestinal solid tumors that have failed, are unavailable to, or are...
Trial ID:
Source:
Title:
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Excerpt:
...Inoperable locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors that have been histopathologically and/or cytologically confirmed and have failed standard therapy, or are...
Trial ID:
More C2 evidence
Source:
Title:
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Excerpt:
...Patients with locally advanced or metastatic HER2-positive/low-expression digestive tract tumors and other solid tumors that are...
Trial ID:
Less C2 evidence
Source:
Title:
BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study
Published date:
12/02/2023
Excerpt:
BL-M07D1 demonstrated encouraging efficacy in heavily pretreated HER2 expressing cancers, especially in HER2+ BC.
Trial ID:
